An artificial intelligence upgrade could be coming soon to a computer program called UpToDate that is used by more than 2 million health care professionals to make decisions about patients' care.

A new atlas of the human brain could help explain abilities like language – and vulnerabilities, like Alzheimer's disease.

Hungarian-born biochemist Katalin Karikó and American immunologist Drew Weissman found that a chemical change to genetic code called mRNA eliminated a problematic side effect when used in vaccines.

Researchers have identified 46 genes that can disrupt a process that is critical to early brain development. The finding could help scientists find new treatments for disorders including autism.

Scientists in Japan are leaders in the development of IVG, new technology that could make sperm and eggs from practically any cell in the body. The results could transform human reproduction.

Some people are finding pharmacies still don't have supply of the shots, and others are having insurance coverage troubles. Here's what's going on.

After Roe v. Wade was overturned, a law still on the books from 1849 left the legality of abortions in dispute in the state. This week, Planned Parenthood resumes services.

At a recent medical gathering, researchers presented their latest hypotheses about what causes – and what could treat – the lingering disease.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

New companies are working to commercialize in vitro gametogenesis, or IVG, a technology that could make human eggs and sperm in the lab from any cell in the body.

Taken after sex, the antibiotic doxycycline can ward off some sexually transmitted illnesses. Doctors are already prescribing it and the CDC is expected to share guidance soon for how best to use it.

Calliope Holingue researches how the microbiome and mind affect each other. She's part of a growing field, exploring how that connection could ultimately improve treatments for mental conditions.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

The Food and Drug Administration approved the first gene therapy for Duchenne muscular dystrophy, but limited access to those ages four and five.

Diseases like Alzheimer's and Parkinson's spread through the brain like a forest fire. A new study suggests how the fire starts.